Northstrive Biosciences has submitted a pre-Investigational New Drug, or pre-IND, meeting request to the FDA for EL-22, a novel myostatin asset ...

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded drugs — not be false or misleading,” contended Pharmaceutical Research and ...

An advocacy group criticizes Hims & Hers Health for allegedly misleading Super Bowl ad promoting weight loss products, violating FDA regulations. Read more here.

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers. The world's largest and longest ...

Investopedia / Joules Garcia An engagement letter is a written agreement that describes the business relationship to be entered into by a client and a company. The letter details the scope of the ...

In this article, we are going to take a look at where Global Partners LP (NYSE:GLP) stands against other oil & gas stocks that are skyrocketing so far in 2025. The oil & gas sector has been quite ...

The stock has performed exceptionally well in recent years, driven by the success of its glucagon-like peptide-1 (GLP-1) receptor agonist drug portfolio ... comment about LLY in its Q3 2024 investor ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

JOHNSON CITY, Tenn. and NASHVILLE, Tenn., Jan. 31, 2025 /PRNewswire/ -- Crown Laboratories, Inc. (“Crown”) and Revance Therapeutics, Inc. (NASDAQ: RVNC ...